New hope for tough lymphoma: glofitamab trial launches in china

NCT ID NCT06481826

Recruiting now Disease control Sponsor: Peking Union Medical College Hospital Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a drug called glofitamab in 20 Chinese patients whose diffuse large B-cell lymphoma has returned or not responded to at least two prior treatments. The goal is to see if the drug can control the cancer and how safe it is. Participants receive glofitamab alone, and researchers will track how long the cancer stays away and any side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Glofitamab
What this could lead to: If it works, this could offer a new treatment option for Chinese patients with hard-to-treat DLBCL who have run out of standard therapies.
What could go wrong: This is a small, early-phase study with only 20 participants, so results may not apply broadly. The drug may cause side effects or fail to control the cancer.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DLBCL - DIFFUSE LARGE B CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diffuse large B-cell lymphoma interdigitating dendritic cell sarcoma relapsed/refractory diffuse large B-cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DLBCL - DIFFUSE LARGE B CELL LYMPHOMA

Contacts and locations

Locations

Peking Union Medical College Hospital
RECRUITING

Beijing, Beijing Municipality, 100730, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.